MVMetin Vural

Metin Vural

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Metin Vural has a total of 128 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Significant Correlation of Dynamic Pan-Immune Inflammation Value and Magnetic Resonance Imaging Response in Patients with Locally Advanced Rectal Cancer Treated with Total Neoadjuvant Therapy

    by Sukran Celikarslan, Duygu Karahacioglu, Bengi Gurses, Fatih Selcukbiricik, Emre Balik, Derya Salim Uymaz, Ahmet Rencuzogullari, Dursun Bugra, Sahin Lacin, Kerim Kaban, et al.

    Background: Accurate identification of complete or near-complete responders after total neoadjuvant therapy (TNT) is critical for selecting candidates for non-operative management in locally advanced rectal cancer (LARC). While static inflammatory biomarkers have been widely investigated, the predictive value of dynamic changes in systemic inflammation during TNT remains unclear. This study evaluated whether changes in the Pan-Immune Inflammation Value (PIV) correlate with magnetic resonance imaging tumor regression grade (mrTRG) and regrowth risk. Methods: Seventy-three patients with LARC treated with TNT between 2018 and 2024 were retrospectively analyzed. Patients were classified as complete/near-complete responders (C-NCRG; mrTRG1–2) or residual disease group (RDG; mrTRG3–5). The PIV was calculated as (platelet × monocyte × neutrophil)/lymphocyte at treatment initiation (first-PIV), three weeks after completion of chemotherapy (last-PIV), and at regrowth (Rg-PIV). Dynamic changes were defined as Δ-PIV (last-PIV minus first-PIV) and ΔRg-PIV (Rg-PIV minus first-PIV). Receiver operating characteristic analysis identified optimal cutoffs, and logistic regression assessed independent associations. Results: The baseline PIV did not differ between groups. Last-PIV and Δ-PIV were significantly lower in the C-NCRG compared with RDG (p = 0.006). A Δ-PIV cutoff of −36.9 discriminated responders (AUC = 0.705; sensitivity 53.7%; specificity 84.4%) and remained independently associated with MRI response in multivariate analysis. In the non-operative management cohort, ΔRg-PIV was significantly lower in patients without regrowth (p = 0.001), with a cutoff of −77.72 (AUC = 0.794; sensitivity 88.9%; specificity 66.7%). Overall survival was superior in the C-NCRG (p = 0.01). Conclusions: A dynamic reduction in the PIV during TNT is significantly associated with favorable MRI response and lower regrowth risk in LARC. PIV dynamics may serve as a noninvasive complementary biomarker to support response assessment and stratification in organ-preservation strategies.

  • Open Access

    The role of T1 hyperintensity in differentiating granulomatous prostatitis from prostate cancer: a retrospective analysis of 31 lesions

    by Selahattin Durmaz, Mert Kılıç, Bilgen Coşkun, Sergin Akpek, Barış Bakır, Tarık Esen, Metin Vural, Emre Altınmakas

    To investigate the multiparametric magnetic resonance imaging (mpMRI) characteristics of granulomatous prostatitis (GP) and share our experience with 31 pathologically confirmed GP lesions in 19 patients. This two-center retrospective study reviewed the pathological and imaging data of 856 patients who underwent prostate biopsy between January 2012 and April 2024. Of these, 19 patients with available prebiopsy mpMRI and a pathologically confirmed diagnosis of GP were included. Additionally, 280 biopsy-naïve patients diagnosed with clinically significant prostate cancer (csPCa) were included as a control group for comparative analysis. Prebiopsy mpMR images of patients with GP were assessed by consensus between two of three radiologists (M.V., B.C., S.D.), evaluating lesion location, size, shape, multifocality, extraprostatic extension (EPE), signal characteristics on T1-, T2-, and diffusion-weighted imaging (DWI), the mean apparent diffusion coefficient (ADCmean) value, enhancement patterns, and prostate imaging reporting and data system (PI-RADS) scores. Statistical analyses were conducted using SPSS version 30.0. In 19 patients, 31 pathologically confirmed GP lesions were identified on prebiopsy mpMRI. Twenty-six lesions were located in the peripheral zone and five in the transitional zone. Multifocal involvement was observed in nine patients (47.3%). Thirty of 31 lesions were hypointense on T2-WI, and seven showed capsular bulging and/or irregularity, suggesting EPE. DWI revealed markedly impeded diffusion in all lesions. The median ADCmean value was 825 × 10-3 mm2/s (IQR: 230 × 10-3 mm2/s). On dynamic contrast-enhanced sequences, 25 lesions showed early enhancement, five showed prolonged enhancement, and one showed prolonged ring enhancement. Based on mpMRI findings, 17 lesions were assigned a PI-RADS score of 4, and 13 lesions were assigned a PI-RADS score of 5. Notably, 22 lesions (71%) in 14 patients with GP (73.7%) exhibited hyperintensity on T1-WI despite no prior prostate biopsy history. Statistical analysis comparing the GP and csPCa groups revealed that hyperintensity on T1-WI was significantly more frequent in GP, both on a per-patient basis (73.7% vs. 3.2%) and a per-lesion basis (71.0% vs. 3.1%) (P < 0.0001 for both). GP shares overlapping imaging features with prostate cancer on mpMRI. However, hyperintensity on T1-WI may serve as a distinguishing feature, potentially reducing unnecessary prostate interventions. Radiologists should consider GP in PI-RADS ≥4 lesions exhibiting T1-WI hyperintensity. Furthermore, given the high incidence of GP following intravesical Bacillus Calmette-Guérin (BCG) therapy, a thorough history of BCG treatment should be obtained. GP is recognized for its tendency to mimic PCa on mpMRI, a finding corroborated by this study. However, T1-WI hyperintensity emerged as a promising distinguishing feature for GP. Incorporating this marker into mpMRI interpretation criteria may help reduce unnecessary prostate interventions and improve patient outcomes.


  • The role of the size and number of index lesion in the diagnosis of clinically significant prostate cancer in patients with PI-RADS 4 lesions who underwent in-bore MRI-guided prostate biopsy

    by Mert Kilic, Serdar Madendere, Metin Vural, Ersin Koseoglu, Mevlana Derya Balbay, Tarik Esen

    Purpose To evaluate the contribution of the size and number of the sampled lesions to the diagnosis of clinically significant prostate cancer (CSPC) in patients who had PI-RADS 4 lesions. Methods In this retrospective study, a total of 159 patients who had PI-RADS 4 lesions and underwent In-bore MRI-Guided prostate biopsy were included. Patients with a lesion classified as Grade Group 2 and above were considered to have CSPC. Univariate and multivariate regression analyses were used to evaluate the factors affecting the diagnosis of prostate cancer (PCa) and CSPC. Results A great majority (86.8%) of the patients were biopsy-naïve. About three-fourths (71.7%) had PCa, and half (54.1%) had CSPC. When the patients were divided into three groups according to the index lesion size (< 5 mm, 5–10 mm, and > 10 mm), the prevalence of PCa was 64.3, 67.5, and 82.4% and the prevalence of CSPC was 42.9, 51.2, and 64.7%, respectively. In multivariate analysis, age, index lesion size, prostate volume (< 50 ml) and being biopsy-naïve were found significant for PCa, while age and prostate volume (< 50 ml) were significant for CSPC. Conclusion The number of lesions was found to be insignificant in predicting PCa and CSPC. While the size of PI-RADS 4 lesions was significant in predicting PCa, it had no significance in detecting CSPC.


  • Open Access

    Pathological Accuracy in Prostate Cancer: Single-Center Outcomes of 3 Different Magnetic Resonance Imaging-Targeted Biopsy Techniques and Random Systematic Biopsy

    by Mert Kılıç, Ömer Acar, Metin Vural, Bülent Çolakoğlu, Barbaros Erhan Çil, Ersin Köseoğlu, Dilek Ertoy Baydar, Abdullah Erdem Canda, Yakup Kordan, Mevlana Derya Balbay, et al.

    Objective: The aim of this study is to compare systematic, cognitive fusion, in-bore, and software fusion prostate biopsies regarding rates of and risk factors for pathological upgrading. Material and methods: Charts of 291 patients with systematic biopsy (n = 105), magnetic resonance imaging- targeted cognitive fusion (n = 58), in-bore (n = 68), and software fusion biopsy (n = 60), and who subsequently underwent radical prostatectomy were retrospectively evaluated. The degree of similarity between the grade groups reported in the biopsy and radical prostatectomy pathology results was recorded. Analyses of the associated factors for concordance and discordance were performed with univariate and multivariate methods. Results: The concordance rates were as follows: systematic biopsy = 42.8%, cognitive fusion-targeted biopsy = 50%, in-bore fusion-targeted biopsy = 61.8, and software fusion biopsy = 58.4%. The upgrade rate of systematic biopsy (46.6%) was higher than cognitive fusion-targeted biopsy (27.6%), in-bore fusiontargeted biopsy (26.4%), and software fusion-targeted biopsy (18.3%). The number of positive cores was significantly associated with grade group concordance for the systematic biopsy group (P = .040). Within the cognitive fusion-targeted biopsy cohort, number of positive cores was the only parameter that exhibited a significant association with grade group concordance in multivariate analysis (P = .044). Considering the in-bore fusion-targeted biopsy group, maximum tumor length was statistically significant (P = .021). In the software fusion-targeted biopsy group, low prostate volume was found to be the only significant predictor for grade group accordance (P = .021). Conclusion: Magnetic resonance imaging-targeted biopsy techniques showed higher concordance and lower upgrade rates compared to systematic biopsy. For systematic biopsy and cognitive fusion-targeted biopsy, the number of positive cores was associated with grade group concordance, while maximum tumor length in in-bore fusion-targeted biopsy and low prostate volume for in-bore fusion-targeted biopsy were associated with grade group concordance. Among the MRI-targeted biopsy methods, in-bore fusion-targeted biopsy and software fusion-targeted biopsy were more accurate than cognitive fusion-targeted biopsy in terms of grade group. Cite this article as: Kılıç M, Acar Ö, Vural M, et al. Pathological accuracy in prostate cancer: Single-center outcomes of 3 different magnetic resonance imaging-targeted biopsy techniques and random systematic biopsy. Turk J Urol. 2022;48(5):346-353.


  • Histologically benign PI‐RADS 4 and 5 lesions contain cancer‐associated epigenetic alterations

    by Ceren Şeref, Ömer Acar, Mert Kılıç, Metin Vural, Yeşim Sağlıcan, Hilal Saraç, Bilgen Coşkun, Ümit İnCe, Tarık Esen, Nathan A. Lack

    Background: The detection rate of clinically significant prostate cancer has improved with the use of multiparametric magnetic resonance imaging (mpMRI). Yet, even with MRI‐guided biopsy 15%–35% of high‐risk lesions (Prostate Imaging‐Reporting and Data System [PI‐RADS] 4 and 5) are histologically benign. It is unclear if these false positives are due to diagnostic/sampling errors or pathophysiological alterations. To better understand this, we tested histologically benign PI‐RAD 4 and 5 lesions for common malignant epigenetic alterations.Materials and Methods: MRI‐guided in‐bore biopsy samples were collected from 45 patients with PI‐RADS 4 (n = 31) or 5 (n = 14) lesions. Patients had a median clinical follow‐up of 3.8 years. High‐risk mpMRI patients were grouped based on their histology into biopsy positive for tumor (BPT; n = 28) or biopsy negative for tumor (BNT; n = 17). From these biopsy samples, DNA methylation of well‐known tumor suppressor genes (APC, GSTP1, and RARβ2) was quantified.Results: Similar to previous work we observed high rates of promoter methylation at GSTP1 (92.7%), RARβ2 (57.3%), and APC (37.8%) in malignant BPT samples but no methylation in benign TURP chips. Interestingly, similar to the malignant samples the BNT biopsies also had increased methylation at the promoter of GSTP1 (78.8%) and RARβ2 (34.6%). However, despite these epigenetic alterations none of these BNT patients developed prostate cancer, and those who underwent repeat mpMRI (n = 8) demonstrated either radiological regression or stability.Conclusions: Histologically benign PI‐RADS 4 and 5 lesions harbor prostate cancer‐associated epigenetic alterations.


  • In-bore MRI-guided prostate biopsy in a patient group with PI-RADS 4 and 5 targets: A single center experience

    by Metin Vural, Bilgen Coskun, Mert Kilic, Selahattin Durmaz, Terman Gumus, Duygu Cengiz, Aslihan Onay, Yesim Saglican, Bulent Colakoglu, Sergin Akpek, et al.


  • Open Access

    The clinical impact of Prostate Imaging–Reporting and Data System classification in patients with haemospermia undergoing multiparametric magnetic resonance imaging of the prostate

    by Mert Kilic, Bilgen Coskun, Metin Vural, Ahmet Musaoglu, Tarik Esen, Mevlana Derya Balbay

    In this study, we evaluated the role of the Prostate Imaging–Reporting and Data System (PI‐RADS) classification of multiparametric magnetic resonance imaging (mpMRI) to determine the likelihood of prostate cancer (PCa) in patients with haemospermia. Fifty‐one patients presenting with haemospermia between 2018 and 2020 were included in this retrospective study. Forty‐two of the patients (82.4%) were over 40 years, and the median prostate‐specific antigen (PSA) level was 1.4 ng/ml. Fourteen of the patients (27.5%) had recurrent haemospermia. All patients underwent mpMRI, and assessments were classified according to PI‐RADS v2. The mpMRI revealed PI‐RADS one to four lesions in 10 (19.6%), 30 (58.8%), 6 (11.8%) and 5 (9.8%) patients respectively. One patient with PI‐RADS 3 and five with PI‐RADS 4 lesions underwent cognitive fusion prostate biopsy depending on MRI findings, and two patients with PI‐RADS 4 lesions were diagnosed with PCa. Patients with haemospermia and risk factors, that is aged over 40 years, a high PSA level or familial history of PCa, need a more thorough evaluation with mpMRI.


  • Can Extraprostatic Extension Be Predicted by Tumor-Capsule Contact Length in Prostate Cancer? Relationship With International Society of Urological Pathology Grade Groups

    by Baris Bakir, Aslıhan Onay, Metin Vural, Ayşe Armutlu, Sevda Özel Yıldız, Tarık Esen

    OBJECTIVE. The objective of our study was to evaluate the relationship between the tumor-capsule contact length, defined as tumor contact length (TCL), and extraprostatic extension (EPE) using the ...


  • The role of T2-weighted images in assessing the grade of extraprostatic extension of the prostate carcinoma

    by Aslihan Onay, Gokhan Ertas, Metin Vural, Evrim Colak, Tarik Esen, Baris Bakir

    Extraprostatic extension (EPE) is an unfavorable prognostic factor and the grade of EPE is also shown to be correlated with the prognosis of prostate cancer. The current study assessed the value of prostate magnetic resonance imaging (MRI) in measuring the radial distance (RD) of EPE and the role of T2 WI signs in predicting the grade of EPE.